ClinicalTrials.gg
CompletedNCT03120520Updated Oct 4, 2019Results posted

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

A Phase 2 interventional study of Plecanatide and Matching placebo in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 36 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2017, registered Apr 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Enrollment
11th of 12
124 · median 800
Started
2017
the only one that year
Phase 2
5 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 9th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to \< 18 years diagnosed with Chronic Idiopathic Constipation.

Read the detailed description

The purpose of the study is to evaluate efficacy, safety, and pharmacokinetics (PK) of oral Plecanatide 0.5, 1.0 and 1.5 mg tablets dosed once a day as compared to matching placebo, when administered for 8 weeks in adolescents with chronic idiopathic constipation.

This study will consist of a 4-week screening period, 8 weeks of treatment, and a 2-week follow-up. The study will assess the effects of Plecanatide on bowel movement frequency and other clinical features of CIC.

03

Conditions studied

  • Chronic Idiopathic Constipation

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female adolescents 12 to less than 18 years of age.
  2. Diagnosed with CIC based on the Rome III criteria for child/adolescent functional constipation (Appendix A).
  3. Patient is able to voluntarily provide written, signed, and dated (personally and via a legally authorized representative [LAR]) assent/ as applicable to participate in the study.
  4. Subject's parent/LAR demonstrates an understanding, ability, and willingness to fully comply with study procedures (e.g., accept venipuncture, willing and able to swallow tablets, accept urine drug screen for opiates) and restrictions.

Key Exclusion Criteria:

  1. The patient has a mental age \<4 years in the investigator's opinion.
  2. The patient has previously been diagnosed with anorectal malformations, neurological deficits, or anatomical anomalies that would constitute a predisposition to constipation.
  3. The patient currently requires iron supplements, amitriptyline, or other tricyclic antidepressants for depression, opioid-containing medications or compounds for pain, or has other conditions that require medications known to cause constipation. A patient with an onset of constipation prior to the use of these medications and who has been on a stable dose for at least 8 weeks prior to Screening might be considered eligible for this study if the investigator deems these medications do not significantly contribute to the patient's constipation. Screening of these patients needs to be approved by the medical monitor and the sponsor.
  4. The patient, if female of (defined as postmenarche), does not agree to practice 1 of the following medically acceptable methods of throughout the study:

    • Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives for a minimum of 1 full cycle (based on the patient's usual menstrual cycle period) before study drug administration.
    • Total abstinence from sexual intercourse since the last menses before study drug administration.
    • Intrauterine device.
    • Double barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream.
  5. The patient follows a diet not considered normal by the investigator for the patient's age, relative to variety of food, caloric content, and quantity. The patient must have been on a stable diet for at least 30 days weeks prior to Screening.
  6. The patient's mobility or normal exercise tolerance is compromised in the investigator's opinion.
  7. The patient has a history of an eating disorder.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Plecanatide 0.5 mg

    Taken orally once daily in the morning for 8 weeks

    Drug: Plecanatide

  • Experimental
    Plecanatide 1.0 mg

    Taken orally once daily in the morning for 8 weeks

    Drug: Plecanatide

  • Experimental
    Plecanatide 1.5 mg

    Taken orally once daily in the morning for 8 weeks

    Drug: Plecanatide

  • Placebo comparator
    Matching placebo

    Taken orally once daily in the morning for 8 weeks

    Drug: Matching placebo

Interventions

  • Also known as: Trulance

  • DrugMatching placebo

    Also known as: No other names

06

What researchers measure

Primary outcomes

  1. Proportion of Overall Responders

    An Overall Responder is a participant who was a Spontaneous Bowel Movement (SBM) responder for the last 2 weeks of the Treatment Period. An SBM responder is defined as a participant who had \>3 SBMs per week. SBM was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. Participants missing with respect to the outcome measure were scored as non-responders.

    Time frame: 8 weeks

Secondary outcomes

  1. Change From Baseline in Weekly Average Stool Consistency Bristol Stool Form Scale (BSFS) Score

    Stool consistency was assessed via the 7-point (1-7) Bristol Stool Form Scale (BSFS) and recorded in the bowel movement (BM) and Symptom Diaries. Lower numbers represent more formed stools; higher numbers represent less formed stools. The weekly mean BSFS score per patient = (total of all BSFS scores reported for a corresponding Spontaneous Bowel Movement (SBM) per time period)/n, where n = number of SBMs scored during the time period. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS types were 1) separate hard lumps, like nuts (hard to pass); 2) sausage-shaped but lumpy; 3) like a sausage but with cracks on its surface; 4) like a sausage or snake, smooth and soft; 5) soft blobs with clear-cut edges (passed easily); 6) fluffy pieces with ragged edges, a mushy stool; 7) watery, no solid pieces, entirely liquid.

    Time frame: 8 weeks

  2. Change From Baseline in the Weekly Rate of Spontaneous Bowel Movements (SBM)

    The weekly Spontaneous Bowel Movement (SBM) totals were derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. SBM is defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours

    Time frame: 8 weeks

  3. Change From Baseline in the Weekly Rate of Complete Spontaneous Bowel Movements (CSBM)

    The weekly Complete Spontaneous Bowel Movement (CSBM) totals are derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline is the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. Spontaneous Bowel Movement (SBM) was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. CSBM was defined as a spontaneous bowel movement with the sense of complete evacuation.

    Time frame: 8 weeks

07

Results

Posted Sep 19, 2019

Participant flow

Participant flow — Overall Study
MilestoneMatching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mg
Started31313032
Completed27272629
Not completed4443
Withdrew: Lost to follow-up1111
Withdrew: Withdrawal by subject3232
Withdrew: Other0100

Outcome measures

PrimaryProportion of Overall Responders

An Overall Responder is a participant who was a Spontaneous Bowel Movement (SBM) responder for the last 2 weeks of the Treatment Period. An SBM responder is defined as a participant who had \>3 SBMs per week. SBM was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. Participants missing with respect to the outcome measure were scored as non-responders.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Proportion of Overall Responders
ParticipantsMatching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mg
Proportion of Overall Responders710127
SecondaryChange From Baseline in Weekly Average Stool Consistency Bristol Stool Form Scale (BSFS) Score

Stool consistency was assessed via the 7-point (1-7) Bristol Stool Form Scale (BSFS) and recorded in the bowel movement (BM) and Symptom Diaries. Lower numbers represent more formed stools; higher numbers represent less formed stools. The weekly mean BSFS score per patient = (total of all BSFS scores reported for a corresponding Spontaneous Bowel Movement (SBM) per time period)/n, where n = number of SBMs scored during the time period. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS types were 1) separate hard lumps, like nuts (hard to pass); 2) sausage-shaped but lumpy; 3) like a sausage but with cracks on its surface; 4) like a sausage or snake, smooth and soft; 5) soft blobs with clear-cut edges (passed easily); 6) fluffy pieces with ragged edges, a mushy stool; 7) watery, no solid pieces, entirely liquid.

Time frame:
8 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Weekly Average Stool Consistency Bristol Stool Form Scale (BSFS) Score
units on a scaleMatching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mg
Change From Baseline in Weekly Average Stool Consistency Bristol Stool Form Scale (BSFS) Score0.98 ± 0.2091.09 ± 0.2091.22 ± 0.2051.06 ± 0.191
SecondaryChange From Baseline in the Weekly Rate of Spontaneous Bowel Movements (SBM)

The weekly Spontaneous Bowel Movement (SBM) totals were derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. SBM is defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours

Time frame:
8 weeks
Reported as:
Least squares mean · Weekly SBMs
Change From Baseline in the Weekly Rate of Spontaneous Bowel Movements (SBM)
Weekly SBMsMatching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mg
Change From Baseline in the Weekly Rate of Spontaneous Bowel Movements (SBM)1.44 ± 0.3321.97 ± 0.3392.06 ± 0.3432.05 ± 0.328
SecondaryChange From Baseline in the Weekly Rate of Complete Spontaneous Bowel Movements (CSBM)

The weekly Complete Spontaneous Bowel Movement (CSBM) totals are derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline is the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. Spontaneous Bowel Movement (SBM) was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. CSBM was defined as a spontaneous bowel movement with the sense of complete evacuation.

Time frame:
8 weeks
Reported as:
Least squares mean · Weekly CSBMs
Change From Baseline in the Weekly Rate of Complete Spontaneous Bowel Movements (CSBM)
Weekly CSBMsMatching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mg
Change From Baseline in the Weekly Rate of Complete Spontaneous Bowel Movements (CSBM)1.30 ± 0.3441.71 ± 0.3481.83 ± 0.3542.11 ± 0.340

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Matching Placebo0/31 (0%)0/31 (0%)4/31 (12.9%)
Plecanatide 0.5 mg0/31 (0%)0/31 (0%)7/31 (22.6%)
Plecanatide 1.0 mg0/30 (0%)0/30 (0%)4/30 (13.3%)
Plecanatide 1.5 mg0/32 (0%)0/32 (0%)3/32 (9.4%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventMatching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mg
NasopharyngitisInfections and infestations1/312/312/301/32
Viral upper respiratory tract infectionInfections and infestations0/310/311/300/32
NeutropeniaBlood and lymphatic system disorders0/310/311/300/32
Acute TonsillitisInfections and infestations1/310/310/300/32
BronchitisInfections and infestations1/310/310/300/32
Infectious MononucleosisInfections and infestations0/311/310/300/32
Pharyngitis streptococcalInfections and infestations0/311/310/300/32
Upper respiratory tract infectionInfections and infestations0/311/310/300/32
Abdominal DiscomfortGeneral disorders1/310/310/300/32
Gilbert's syndromeCongenital, familial and genetic disorders0/311/310/300/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Matching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mgTotal
Mean14.6 ± 1.6115.1 ± 1.4814.5 ± 1.8914.6 ± 1.5214.7 ± 1.62
Sex: Female, Male
Sex: Female, Male(Participants)Matching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mgTotal
Female1717171869
Male1414131455
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Matching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mgTotal
Hispanic or Latino2121232792
Not Hispanic or Latino10107532
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Matching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mgTotal
American Indian or Alaska Native00000
Asian01012
Native Hawaiian or Other Pacific Islander00000
Black or African American653216
White24242729104
More than one race11002
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Matching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mgTotal
United States31313032124
Baseline Stool Consistency
Baseline Stool Consistency(units on a scale)Matching PlaceboPlecanatide 0.5 mgPlecanatide 1.0 mgPlecanatide 1.5 mgTotal
Mean2.17 ± 0.9322.0 ± 1.1902.08 ± .8992.29 ± 1.2982.13 ± 1.140
08

Study locations

36 sites
  • Synergy Research Site
    Foley, Alabama, United States
  • Synergy Research Site
    Jonesboro, Arkansas, United States
  • Synergy Research Site
    Cerritos, California, United States
  • Synergy Research Site
    Corona, California, United States
  • Synergy Research Site
    Downey, California, United States
  • Synergy Research Site
    Huntington Beach, California, United States
  • Synergy Research Site
    Sacramento, California, United States
  • Synergy Research Site
    Ventura, California, United States
  • Synergy Research Site
    Wilmington, Delaware, United States
  • Synergy Research Site
    DeLand, Florida, United States
  • Synergy Research Site
    Doral, Florida, United States
  • Synergy Research Site
    Hialeah, Florida, United States
  • Synergy Research Site
    Miami, Florida, United States
  • Synergy Research Site
    Orlando, Florida, United States
  • Synergy Research Site
    Tampa, Florida, United States
  • Synergy Research Site
    Snellville, Georgia, United States
  • Synergy Research Site
    Thomaston, Georgia, United States
  • Synergy Research Site
    Idaho Falls, Idaho, United States
  • Synergy Research Site
    Meridian, Idaho, United States
  • Synergy Research Site
    Nicholasville, Kentucky, United States
  • Synergy Research Site
    Crowley, Louisiana, United States
  • Synergy Research Site
    Bellevue, Nebraska, United States
  • Synergy Research Site
    Omaha, Nebraska, United States
  • Synergy Research Site
    Fayetteville, North Carolina, United States
  • Synergy Research Site
    Cincinnati, Ohio, United States
  • Synergy Research Site
    Columbus, Ohio, United States
  • Synergy Research Site
    Dayton, Ohio, United States
  • Synergy Research Site
    Gresham, Oregon, United States
  • Synergy Research Site
    Jackson, Tennessee, United States
  • Synergy Research Site
    Kingsport, Tennessee, United States
  • Synergy Research Site
    Memphis, Tennessee, United States
  • Synergy Research Site
    Corpus Christi, Texas, United States
  • Synergy Research Site
    Houston, Texas, United States
  • Synergy Research Site
    McAllen, Texas, United States
  • Synergy Research Site
    San Antonio, Texas, United States
  • Synergy Research Site
    Newport News, Virginia, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2018, 20 months.

Results were first posted in Sep 2019, 1 year after primary completion.

Of 24 industry-sponsored phase 2 interventional studies under Constipation, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's 20 months is close to that.

Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2017
First posted
Apr 19, 2017
StartActual
Jan 2017
Primary completionActual
Sep 7, 2018
CompletionActual
Sep 7, 2018
Results first posted
Sep 19, 2019
Last update
Oct 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03120520
Responsible party
Sponsor
First posted
Apr 19, 2017
Start date
Jan 2017
Primary completion
Sep 7, 2018
Completion
Sep 7, 2018
Results posted
Sep 19, 2019
Last update
Oct 4, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion